JP2024522175A5 - - Google Patents

Info

Publication number
JP2024522175A5
JP2024522175A5 JP2023575701A JP2023575701A JP2024522175A5 JP 2024522175 A5 JP2024522175 A5 JP 2024522175A5 JP 2023575701 A JP2023575701 A JP 2023575701A JP 2023575701 A JP2023575701 A JP 2023575701A JP 2024522175 A5 JP2024522175 A5 JP 2024522175A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
weeks
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522175A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032979 external-priority patent/WO2022261417A1/en
Publication of JP2024522175A publication Critical patent/JP2024522175A/ja
Publication of JP2024522175A5 publication Critical patent/JP2024522175A5/ja
Pending legal-status Critical Current

Links

JP2023575701A 2021-06-11 2022-06-10 Ｓｔ２アンタゴニストによる慢性閉塞性肺疾患の治療方法 Pending JP2024522175A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209624P 2021-06-11 2021-06-11
US63/209,624 2021-06-11
PCT/US2022/032979 WO2022261417A1 (en) 2021-06-11 2022-06-10 Method for treating chronic obstructive pulmonary disease with an st2 antagonist

Publications (2)

Publication Number Publication Date
JP2024522175A JP2024522175A (ja) 2024-06-11
JP2024522175A5 true JP2024522175A5 (enExample) 2025-06-17

Family

ID=82458702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575701A Pending JP2024522175A (ja) 2021-06-11 2022-06-10 Ｓｔ２アンタゴニストによる慢性閉塞性肺疾患の治療方法

Country Status (12)

Country Link
US (1) US20240228638A1 (enExample)
EP (1) EP4352101A1 (enExample)
JP (1) JP2024522175A (enExample)
KR (1) KR20240019831A (enExample)
CN (1) CN117980333A (enExample)
AU (1) AU2022289017A1 (enExample)
BR (1) BR112023025863A2 (enExample)
CA (1) CA3221924A1 (enExample)
IL (1) IL308597A (enExample)
MX (1) MX2023014658A (enExample)
TW (1) TW202317622A (enExample)
WO (1) WO2022261417A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CA3263546A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Limited ENSIFENTRINE (RPL-554) FOR THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物
CN122121878A (zh) * 2023-09-06 2026-05-29 维罗纳制药有限公司 用于治疗慢性阻塞性肺病（copd）的恩塞芬汀
TW202540173A (zh) * 2024-04-04 2025-10-16 英商梅迪繆思有限公司 治療及選擇對象之方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2

Similar Documents

Publication Publication Date Title
Corren New targeted therapies for uncontrolled asthma
EP2627673B1 (en) Therapies for improving pulmonary function
US20180057582A1 (en) Methods of treatment of eosinophilic bronchitis with an anti-il-5 antibody
Wilsmann-Theis et al. Palmoplantar pustulosis–a cross-sectional analysis in Germany
Ilmarinen et al. Prevalence of patients eligible for anti-IL-5 treatment in a cohort of adult-onset asthma
US10577414B2 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
EP3282258A1 (en) Methods for predicting risk of developing hypertension
EP3685857A1 (en) Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
EP3762015B1 (en) Guselkumab for use in the treatment of crohn's disease with a dosage regimen
Sposato et al. Effects of omalizumab in severe asthmatics across ages: a real life Italian experience
Liu et al. Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study
Suzukawa et al. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab
US20180196065A1 (en) Novel assay to detect human periostin
KR20230067604A (ko) 중등도 내지 중증 천식의 치료를 위한 덱스프라미펙솔의 용도
Garg et al. Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity
Crossley et al. Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease? D. Crossley et al.
Yamashita et al. Tezepelumab improved chronic rhinosinusitis with nasal polyps in a patient with aspirin exacerbated respiratory disease
Presotto et al. Clinical characterization of a novel alpha1-antitrypsin null variant: PiQ0Heidelberg
Zorampari et al. Serum dipeptidyl peptidase-4 and eosinophil cationic protein levels in patients of bronchial asthma
EP4039819B1 (en) Method for assessing risk of cutaneous adverse drug reactions caused by epidermal growth factor receptor inhibitor, test kit thereof, and use thereof
RU2023135621A (ru) Способ лечения хронической обструктивной болезни легких антагонистом st2
TW202110479A (zh) 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
Kupryś-Lipińska et al. Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia
CN115768791B (zh) 涉及过量游离light的方法和治疗
HK40090654A (en) Use of dexpramipexole for the treatment of moderate to severe asthma